Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ubiquinol acetate is a stabilized ester derivative of ubiquinol, which is the reduced, electron-rich form of Coenzyme Q10 (CoQ10). Developed as a nutraceutical and pharmaceutical ingredient, it serves as a precursor that is converted into active ubiquinol within the body. Ubiquinol is a vital component of the mitochondrial electron transport chain, facilitating the transfer of electrons to generate adenosine triphosphate (ATP). Additionally, it acts as a potent lipid-soluble antioxidant, protecting cell membranes and lipoproteins from oxidative damage. The acetate formulation is specifically designed to improve the stability of ubiquinol, which is otherwise highly susceptible to oxidation back to ubiquinone (the oxidized form of CoQ10). It is primarily utilized in formulations targeting cardiovascular health, mitochondrial support, and healthy aging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ubiquinol acetate.